CHALLENGES AND NEW DIRECTIONS IN OBESITY MANAGEMENT

LIFESTYLE MODIFICATION PROGRAMS, PHARMACOTHERAPY, AND BARIATRIC SURGERY

Authors

  • Marwan El Ghoch Department of Nutrition and Dietetics, Faculty of Health Sciences; Beirut Arab University, P.O. Box 11-5020 Riad El Solh, Beirut, Lebanon.
  • Rajaa Fakhoury Department of Nutrition and Dietetics, Faculty of Health Sciences; Beirut Arab University, P.O. Box 11-5020 Riad El Solh, Beirut, Lebanon.

DOI:

https://doi.org/10.15586/jptcp.v26i2.599

Keywords:

Bariatric surgery, Lifestyle modification, Obesity, Sarcopenic obesity, Weight loss, Weight regain

Abstract

Obesity is a growing health problem worldwide, and it is associated with serious medical and psychosocial comorbidities, impairment of health-related quality of life (HRQoL) and an increased risk of mortality. This article aims to discuss challenges faced by health-care providers when managing patients with obesity and to highlight sustainable policies in clinical practice and future research. All health professionals dealing with obesity should consider lifestyle-modification programmes within a  multidisciplinary setting as the key element of weight management. However, standardisation is needed in terms of nature, content and duration of these programmes in order to facilitate their implementation in clinical practice at different levels. Moreover, health professionals should be aware that these programmes, for patients indicating “non-response,” can be combined with recently approved anti-obesity drugs such as liraglutide, naltrexone/bupropion, lorcaserin and phentermine/topiramate, as well as with relatively less invasive bariatric surgery techniques such as Lap Band, endoscopic sleeve gastroplasty and gastric bypass. In any case, neither anti-obesity medication nor bariatric surgery should be considered as a miracle treatment in itself.  At  the  same  time,  the  field  of   obesity  is  still  lacking  in  literature  on  some  hot topics that need further investigation, including (i) a new phenotype termed sarcopenic obesity, to clarify its  definition,  potential  health  consequences  and  eventual  treatment  if   necessary;  (ii)  issues  that  go beyond body weight, for instance, HRQoL that has been poorly studied in some populations affected by obesity;  and  (iii)  the  long-term  effect  of   sleeve  gastrectomy  technique,  which  is  becoming  the  most commonly used bariatric surgical procedure, perhaps to be studied using long-term randomised controlled trials that guarantee completeness of  follow-up, in order to avoid misunderstanding and bias in interpretation of  results.

References

Collaborators GBDO. Health effects of over-weight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377:13–27. http://dx.doi. org/10.1056/NEJMoa1614362

Durrer Schutz D, Busetto L, Dicker D, Farpout-Lambert N, Pryke R, Toplak H, et al. European practical and patient-centred guidelines for adult obesity management in primary care. Obes Facts. 2019;12:40–66. http:/ /dx.doi.org/10.1159/ 000496183

El Ghoch M, Calugi S, Dalle Grave R. Weight cycling in adults with severe obesity: A longitu-dinal study. Nutr Diet. 2018;75:256–62. http://dx. doi.org/10.1111/1747-0080.12387

Wadden TA, Butryn ML, Wilson C. Lifestyle modification for the management of obesity. Gastroenterology. 2007;132:2226–38. http://dx. doi.org/10.1053/j.gastro.2007.03.051

Dalle Grave R, Calugi S, El Ghoch M. Lifestyle modification in the management of obesity: Achievements and challenges. Eat Weight Disord. 2013;18:339–49. http://dx.doi.org/10.1007/s40519-013-0049-4

Digenio AG, Mancuso JP, Gerber RA, Dvorak RV. Comparison of methods for deliver-ing a lifestyle modification program for obese patients: A randomized trial. Ann Intern Med. 2009;150:255–62. http://dx.doi.org/ 10.7326/0003-4819-150-4-200902170-00006

Kreidieh D, Itani L, El Kassas G, El Masri D, Calugi S, Dalle Grave D,et al. Long-term lifestyle-modification programs for over-weight and obesity management in the Arab States: Systematic review and meta-analysis. Curr Diabetes Rev. 2018;14:550–8. doi.10.21741573399813666170619085756

Wadden TA, Webb VL, Moran CH, Bailer BA. Lifestyle modification for obesity: New develop-ments in diet, physical activity, and behavior ther-apy. Circulation. 2012;125:1157–70. http://dx.doi. org/10.1161/ CIRCULATIONAHA.111.039453

Castelnuovo G, Pietrabissa G, Manzoni GM, Cattivelli R, Rossi A, Novelli Met al. Cognitive behavioral therapy to aid weight loss in obese patients: Current perspectives. Psychol Res Behav Manag. 2017;10:165–73. http://dx.doi. org/10.2147/PRBM.S113278

Cooper Z, Doll HA, Hawker DM, Byrne S, Bonner G, Eeley E. Testing a new cognitive behavioural treatment for obesity: A randomized controlled trial with three-year fol-low-up. Behav Res Ther. 2010;48:706–13. http:// dx.doi.org/10.1016/ j.brat.2010.03.008

Ogata K, Koyama KI, Amitani M, Amitani H, Asakawa A, Inui A.. The effectiveness of cognitive behavioral therapy with mindfulness and an Internet intervention for obe-sity: A case series. Front Nutr. 2018;5:56. http:// dx.doi.org/10.3389/ fnut.2018.00056

Barrett S, Begg S, O’Halloran P, Kingsley M. Integrated motivational interviewing and cognitive behaviour therapy for lifestyle mediators of overweight and obesity in community-dwelling adults: A sys-tematic review and meta-analyses. BMC Public Health. 2018;18:1160. http://dx.doi.org/10.1186/ s12889-018-6062-9

Daneschvar HL, Aronson MD, Smetana GW. FDA-approved anti-obesity drugs in the United States. Am J Med. 2016;129: 879.e871–876. http://dx.doi.org/10.1016/j.amjmed. 2016.02.009

Srivastava G, Apovian C. Future pharmacother-apy for obesity: New anti-obesity drugs on thehorizon. Curr Obes Rep. 2018;7:147–61. http:// dx.doi.org/10.1007/s13679-018-0300-4

Busetto L, Dicker D, Azran C, Batterham RL, Farpour-Lambert N, Fried M. Obesity man-agement task force of the European Association for the study of obesity released “practical recom-mendations for the post-bariatric surgery medi-cal management.” Obes Surg. 2018;28:2117–21. http:// dx.doi.org/10.1007/s11695-018-3283-z

O’Brien PE. Controversies in bariatric sur-gery. Br J Surg. 2015;102:611–18. http://dx.doi. org/10.1002/bjs.9760

Velapati SR, Shah M, Kuchkuntla AR, Abu-Dayyeh B, Grothe K, Hurt RT et al. Weight regain after bariatric surgery: Prevalence, etiology, and treatment. Curr Nutr Rep. 2018;7:329–34. http:// dx.doi.org/10.1007/s13668-018-0243-0

Kreidieh D, Itani L, El Masri D, Tannir H, Citarella R, El Ghoch M. Association between sarcopenic obesity, type 2 diabetes, and hypertension in overweight and obese treatment-seeking adult women. J CardiovascDev Dis. 2018;5. http:/ /dx.doi.org/10.3390/ jcdd5040051

El Ghoch M, Calugi S, Dalle Grave R. Sarcopenic obesity: Definition, health consequences and clin-ical management. Open Nutr J. 2018;12:70–3. http://dx.doi.org/10.2174/1874288201812010070

Itani L, Calugi S, Dalle Grave R, Kreidieh D, El Kassas G, El Masri D et al. . The associ-ation between body mass index and health-related quality of life in treatment-seeking Arab adults with obesity. Med Sci (Basel). 2018;6:1–9 http://dx. doi.org/ 10.3390/medsci6010025

O’Brien PE, Hindle A, Brennan L, Skinner S, Burton P, Smith A. Long-term outcomes after bariatric surgery: A sys-tematic review and meta-analysis of weight loss at 10 or more years for all bariatric procedures and a single-centre review of 20-year outcomes after adjustable gastric banding. Obes Surg. 2019;29:3–14. http://dx.doi.org/ 10.1007/s11695-018-3525-0

Published

2019-05-17

How to Cite

Ghoch, M. E., & Fakhoury, R. (2019). CHALLENGES AND NEW DIRECTIONS IN OBESITY MANAGEMENT: LIFESTYLE MODIFICATION PROGRAMS, PHARMACOTHERAPY, AND BARIATRIC SURGERY. Journal of Population Therapeutics and Clinical Pharmacology, 26(2), e1-e4. https://doi.org/10.15586/jptcp.v26i2.599
More Citation Formats

Issue

Section

Articles

How to Cite

Ghoch, M. E., & Fakhoury, R. (2019). CHALLENGES AND NEW DIRECTIONS IN OBESITY MANAGEMENT: LIFESTYLE MODIFICATION PROGRAMS, PHARMACOTHERAPY, AND BARIATRIC SURGERY. Journal of Population Therapeutics and Clinical Pharmacology, 26(2), e1-e4. https://doi.org/10.15586/jptcp.v26i2.599